<DOC>
	<DOC>NCT01723566</DOC>
	<brief_summary>Understanding the clinical practice of treatment of cardiac rhythm disorders all over the world and understanding the clinical outcomes of the treatment with its cardiac rhythm products in real world patient population is essential for Medtronic to be able to effectively develop new products and adjust existing products. In addition Medtronic is committed to monitor the safety of its products throughout the entire life cycle to ensure maximum product reliability. The Panorama 2 registry will enable Medtronic to increase data collection of clinical practice with Medtronic implantable Cardiac Rhythm and Disease Management (CRDM) devices in various regions across the world and on product reliability of its CRDM devices.</brief_summary>
	<brief_title>PANORAMA 2 Observational Study</brief_title>
	<detailed_description />
	<mesh_term>Arrhythmias, Cardiac</mesh_term>
	<criteria>Inclusion criteria: Patient is 18 years of age or older (lower age limit dependent on local law: to be specified in countryspecific addendum to the clinical investigational plan, if applicable) Patient or Legally Authorized Representative provides signed and dated authorization and/or consent per institution and local requirements Patient will be treated with a commercially available implantable Medtronic CRDM device/ Vitatron device within maximally 30 days after enrollment or within 3 days prior to enrollment Exclusion criterion: â€¢ Patient has exclusion criteria per local law (to be specified in countryspecific addendum to the clinical investigational plan, if applicable)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>